ABBOTT LABORATORIES
10-Q, EX-27, 2000-08-03
PHARMACEUTICAL PREPARATIONS
Previous: ABBOTT LABORATORIES, 10-Q, EX-12, 2000-08-03
Next: WORLDS COM INC, SB-2, 2000-08-03



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED STATEMENT OF EARNINGS FOR THE SIX MONTHS ENDED JUNE 30,
2000, AND THE CONDENSED CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2000, AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<EXCHANGE-RATE>                                      1
<CASH>                                         840,149
<SECURITIES>                                   144,102
<RECEIVABLES>                                2,233,933
<ALLOWANCES>                                   193,056
<INVENTORY>                                  1,684,307
<CURRENT-ASSETS>                             6,898,036
<PP&E>                                       9,938,898
<DEPRECIATION>                               5,168,128
<TOTAL-ASSETS>                              14,964,081
<CURRENT-LIABILITIES>                        4,188,266
<BONDS>                                      1,326,416
                                0
                                          0
<COMMON>                                     2,074,238
<OTHER-SE>                                   6,110,156
<TOTAL-LIABILITY-AND-EQUITY>                14,964,081
<SALES>                                      6,723,331
<TOTAL-REVENUES>                             6,723,331
<CGS>                                        3,026,701
<TOTAL-COSTS>                                3,026,701
<OTHER-EXPENSES>                               682,959<F1>
<LOSS-PROVISION>                              (33,883)
<INTEREST-EXPENSE>                              65,233
<INCOME-PRETAX>                              1,887,889
<INCOME-TAX>                                   509,730
<INCOME-CONTINUING>                          1,378,159
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,378,159
<EPS-BASIC>                                       0.89
<EPS-DILUTED>                                     0.88
<FN>
<F1>OTHER EXPENSES CONSISTS OF RESEARCH AND DEVELOPMENT EXPENSE.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission